Does Maternal Body Mass Index Affect the Quantity of Circulating Fetal Cells Available to Use for Cell-Based Noninvasive Prenatal Test in High-Risk Pregnancies?

Author Archives: WebMast

Does Maternal Body Mass Index Affect the Quantity of Circulating Fetal Cells Available to Use for Cell-Based Noninvasive Prenatal Test in High-Risk Pregnancies?

Kruckow S, Schelde P, Hatt L, Ravn K, Petersen OB, Uldbjerg N, Vogel I, Singh R. We present the first study that investigates the effect of maternal body mass index (BMI) on the quantity of circulating fetal cells available to use in cell-based noninvasive prenatal test (cbNIPT). cbNIPT has been proposed as a superior alternative to noninvasive prenatal test from cell-free fetal DNA. Kølvraa […]

read more

Guest Symposium at ARCEDI Biotech ApS

read more

27-11-2017 PRESS RELEASE

ARCEDI BIOTECH TO PRESENT AT FIFTH ANNUAL ADVANCES IN PRENATAL MOLECULAR DIAGNOSTICS CONFERENCE – Additional Presentations and Panel Discussions Highlight Advances in Cell-Based Non-Invasive Prenatal Testing – Vejle, Denmark, November 27, 2017 – ARCEDI Biotech ApS, a company developing technologies for rare fetal cell detection for use in prenatal diagnostic applications, today announced that Ripudaman […]

read more

13-11-2017 PRESS RELEASE

ARCEDI BIOTECH ANNOUNCES LAUNCH OF FIRST AND ONLY NON-INVASIVE PRENATAL TESTING BASED ON FETAL CELLS IN MATERAL BLOOD IN DENMARK – Comparative Non-Invasive Alternative to Invasive “Gold-Standard” Testing – Vejle, Denmark, November 13, 2017 – ARCEDI Biotech ApS, a company developing technologies for rare fetal cell detection for use in prenatal diagnostic applications, today announced […]

read more

6-11-17 PRESSEMEDDELELSE (Dansk)

PRESSEMEDDELELSE Ny og lovende fosterdiagnostik er mere skånsom for gravide I fremtiden vil det måske blive muligt for gravide at undgå en moderkageprøve. En simpel blodprøve vil kunne give den samme detaljerede viden om fosteret. Det viser ny forskning fra Aarhus Universitetshospital og det danske firma Arcedi Biotech. Mange gravide bliver bekymrede, hvis de får […]

read more

BREAKING – Simpel blodprøve kan erstatte moderkageprøve hos gravide

06. nov. 2017, 11:27 af Rizau Ny og lovende fosterdiagnostik er mere skånsom over for gravide, viser ny forskning. I fremtiden bliver det måske muligt for gravide at undgå en moderkageprøve. En simpel blodprøve kan give den samme detaljerede viden om fosteret. Det viser ny forskning fra Aarhus Universitetshospital og det danske firma Arcedi Biotech. […]

read more

ARCEDI Biotech Readying Cell-Based NIPT for Commercialization as Clinical Studies Continue (GenomeWeb)

Oct 30, 2017 Julia Karow NEW YORK (GenomeWeb) – Arcedi Biotech of Denmark has been collaborating with six Danish hospitals to clinically validate its technology for isolating circulating fetal cells from maternal blood and analyzing their DNA for noninvasive prenatal diagnostics. Arcedi hopes to commercialize the technology in the near future through a large diagnostic […]

read more

On the road to replacing invasive testing with cell‐based NIPT: Five clinical cases with aneuploidies, microduplication, unbalanced structural rearrangement, or mosaicism

Objective: Trophoblastic fetal cells harvested from maternal blood have the capacity to be used for copy number analyses in a cell‐based non‐invasive prenatal test (cbNIPT). Potentially, this will result in increased resolution for detection of subchromosomal aberrations due to high quality DNA not intermixed with maternal DNA. We present 5 selected clinical cases from first […]

read more

12-10-17 PRESS RELEASE

ARCEDI BIOTECH ANNOUNCES PUBLICATION HIGHLIGHTING SUCCESS OF CUTTING-EDGE CELL-BASED NONINVASIVE PRENATAL TESTING TO DETECT ANEUPLOIDY AND SUBCHROMOSOMAL ABNORMALITIES IN FIRST TRIMESTER PREGNANCIES – Preliminary Results Identical to Invasive “Gold-Standard” Testing – Vejle, Denmark, October 12, 2017 – ARCEDI Biotech ApS, a company developing technologies for rare fetal cell detection for use in prenatal diagnostic applications, […]

read more

A Noninvasive Future – Prenatal Genetic Testing Looks to Single-Cell Methods as the Next Frontier

ClinicalOmics By Helen Albert|August 2017 Prenatal genetic testing has advanced enormously over the last few decades. Amniocentesis and chorionic villus sampling (CVS) have been performed to diagnose fetal abnormalities for many years, but these tests are invasiveand not without problems. The risk for miscarriage is low (approximately 1 in 1000 for amniocentesis and 1 in 500 […]

read more